



2nd International
Workshop on
Liver & Gut
Fibrosis

26-27 OCTOBER 2023
VALENCIA, SPAIN

PROGRAMME

THURSDAY 26TH OCTOBER 2023

8:45 - 9:15 am Registration

9:15 am Welcome & overview of the workshop

9:30 - 10:45 am **FIBROSIS: STATE-OF-THE-ART**

Chairs: Jordi Gracia-Sancho (IDIBAPS, Barcelona) & Marta Maia Boscá-Watts (Hospital Clínic Universitario, Valencia)

9:30 - 10:05 am *Mechanisms and clinical trial endpoints for structuring Crohn's disease.* Florian Rieder (Cleveland Clinic Foundation, Ohio)

10:05 - 10:40 am *Liver fibrosis in ALD and NAFLD.* Ramón Bataller (Hospital Clínic Barcelona)

10:45 - 11:30 am Coffee break

11:30 am - 1:10 pm **FACTORS INFLUENCING THE DEVELOPMENT OF FIBROSIS**

Chairs: Rubén Francés (Miguel Hernández University, Alicante) & Ana Blas-García (University of Valencia)

11:30 - 11:50 am *Sinusoidal communication in liver fibrosis.* Anabel Fernández-Iglesias (IDIBAPS, Barcelona)

11:50 am - 12:10 pm *Epigenetic landscape in liver fibrosis.* Maite García Fernández-Barrena (CIMA University of Navarra, Pamplona)

12:10 - 12:30 pm *Regulation of fibroblast-monocyte interactions: how do we TWEAK the system?* Mario C. Manresa (University College Dublin)

12:30 - 12:50 pm *Lipotoxicity and fibrosis.* Fabio Marra (University of Florence)

12:50 - 1:10 pm *Autophagy in liver fibrosis: roles, mechanisms and targets.* Nadezda Apostolova (University of Valencia)

1:10 - 2:30 pm Lunch

2:30 - 3:50 pm **CUTTING-EDGE APPROACHES TO THE STUDY OF FIBROSIS**

Chairs: Javier Cubero (Complutense University of Madrid) & Azucena Salas (Hospital Clínic Barcelona)

2:30 - 2:50 pm *Hepatic pathways in NAFLD progression: insights from multi-omics approaches.* Olivier Govaere (KU Leuven, Leuven)

2:50 - 3:10 pm *Multi-omics in IBD: overview of observations and take-aways.* Urko M. Marigorta (CIC BioGUNE, Bilbao)

3:10 - 3:30 pm *Using iPSCs to understand liver fibrosis.* Pau Sancho-Bru (IDIBAPS, Barcelona)

3:30 - 3:50 pm *Biomarkers in IBD.* Marianne Spalinger (University Hospital Zurich)

3:50 - 4:45 pm Coffee break & Poster session

4:45 - 5:45 pm **FIBROSIS IN OTHER ORGANS AND TISSUES**

Chairs: Sara Calatayud & Elena Ortiz (University of Valencia)

4:45 - 5:05 pm *Mechanisms of old fibrosis by impaired degradation.* Antonio Vidal-Puig (Wellcome-MRC Institute of Metabolic Science and MRC Metabolic Diseases Unit, University of Cambridge)

5:05 - 5:25 pm *Impact of diffuse myocardial fibrosis in heart failure.* Arantxa González Miqueo (CIMA University of Navarra, Pamplona)

5:25 - 5:45 pm *Role of cellular senescence in the development of lung fibrosis.* Jacobo Sellares (Hospital Clínic Barcelona)

6:30 - 8:30 pm Tour of the city

8:30 pm Drinks and canapés. Only YOU Hotel (The City Lover Room)

FRIDAY 27TH OCTOBER 2023

9:00 - 11:00 am ORAL PRESENTATIONS

Chairs: David Martí-Aguado (Hospital Clínico Universitario, Valencia) & Jesús Cosín (University of Valencia)

9:00 - 9:10 AM: *Protease-driven lysosomal activity is a core mechanism for macrophage driven collagen remodeling during liver and kidney fibrosis.* **María Fernández-Fernández** (Institute of Biomedical Research of Barcelona)

9:10 - 9:20 AM: *Mg²⁺ homeostasis in cholestatic liver diseases: potential therapeutic target.* **Naroa Goikoetxea-Usandizaga** (CICBioGUNE)

9:20 - 9:30 AM: *Microbiota dysbiosis, altered metabolomic profile and metabolite-sensing GPCRs expression is found in ileal resections from fibrotic-CD patients.* **Cristina Bauset** (University of Valencia)

9:30 - 9:40 AM: *Exploring the role of X-binding protein-1 (XBP1) in the gut- liver axis during alcohol-related liver disease (ArLD).* **Carlos Sanz-García** (Complutense University)

9:40 - 9:50 AM: *Peptidylprolyl isomerase C in chronic liver disease: pathogenic or protective mechanism.* **Isabel Fuster-Martínez** (University of Valencia)

9:50 - 10:00 AM: *Dissecting submucosal fibroblast populations of human colon Crohn's Disease patients through spatial transcriptomics.* **Victoria Gudiño** (IDIBAPS)

10:00 - 10:10 AM: *Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis.* **Stephanie C. Izasa** (Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa)

10:10 - 10:20 AM: *A novel senolytic nanoformulation targeting the hepatic sinusoid improves hepatic function and fibrosis in experimental models of aging.* **David Sanfeliu-Redondo** (IDIBAPS)

10:20 - 10:30 AM: *The TNF superfamily factor TWEAK promotes colonic inflammatory fibroblast differentiation and fibroblast-monocyte interaction.* **Carlos Matellan** (University College Dublin)

10:30 - 10:40 AM: *Identification and assessment of circulating biomarkers for the evaluation of liver disease severity in NAFLD patients.* **Douglas Maya-Miles** (Instituto de Biomedicina de Sevilla)

10:40 - 10:50 AM: *Oral administration *B. longum* sub. *Infantis* 16p1 approximates gut microbiota towards eubiosis and reduces fibrosis in the experimental model of CCl₄-induced liver injury.* **Rubén Francés** (Universidad Miguel Hernández)

11:00 am - 12:00 pm Coffee break & Poster session

12:00 - 1:20 pm THERAPEUTIC APPROACHES TO FIBROSIS

Chairs: Jaume Bosch (University of Bern) & Ana Gutiérrez (Hospital General Universitario, Alicante)

12:00 - 12:20 pm *Characterization of molecular targets in ileal fibrosis: a starting point for the development of new therapies.*

María Dolores Barrachina (University of Valencia)

12:20 - 12:40 pm *Clinical trials in NAFLD-fibrosis.*

Manuel Romero-Gómez (Hospital Virgen del Rocío-IBiS, Seville)

12:40 - 1:00 pm *Treating fibrosis in IBD: a challenge for the gastroenterologist.*

Marta-Maia Boscá-Watts (Hospital Clínico Universitario, Valencia)

1:00 - 1:20 pm *Pathophysiology of advanced liver disease.*

Rafael Bañares (Hospital Gregorio Marañón, Madrid)

1:30 - 1:45 pm Best Communication Award and concluding remarks

2:00 - 3:30 pm Lunch